Department of Translational Science and Molecular Medicine,
Neuroscience Program,
Department of Translational Neuroscience,
Mercy Health Hauenstein Neuroscience Medical Center,
College of Human Medicine,
Department of Translational Neuroscience, Mercy Health Hauenstein Neuroscience Medical Center
Caryl E. Sortwell has not added Biography.
If you are Caryl E. Sortwell and would like to personalize this page please email our Author Liaison for assistance.
Striatal Pleiotrophin Overexpression Provides Functional and Morphological Neuroprotection in the 6-Hydroxydopamine Model.
Molecular therapy : the journal of the American Society of Gene Therapy Oct, 2011 | Pubmed ID: 22008908
Subthalamic Nucleus Stimulation Increases Brain Derived Neurotrophic Factor in the Nigrostriatal System and Primary Motor Cortex.
Journal of Parkinson's disease May, 2011 | Pubmed ID: 22328911
Endogenous neural precursors influence grafted neural stem cells and contribute to neuroprotection in the parkinsonian rat.
The European journal of neuroscience Mar, 2012 | Pubmed ID: 22417168
Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
PloS one , 2013 | Pubmed ID: 24312298
Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Mar, 2015 | Pubmed ID: 25267343
Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain.
Neurobiology of aging Feb, 2015 | Pubmed ID: 25457558
Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.
Experimental neurology Apr, 2015 | Pubmed ID: 25681575
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Neurobiology of disease May, 2015 | Pubmed ID: 25771169
The longitudinal transcriptomic response of the substantia nigra to intrastriatal 6-hydroxydopamine reveals significant upregulation of regeneration-associated genes.
PloS one , 2015 | Pubmed ID: 25992874
Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Neurobiology of disease Oct, 2015 | Pubmed ID: 26093169
High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine.
PloS one , 2015 | Pubmed ID: 26222442
Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience Nov, 2015 | Pubmed ID: 26558771
Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.
Methods in molecular biology (Clifton, N.J.) , 2016 | Pubmed ID: 26611600
Impact of age and vector construct on striatal and nigral transgene expression.
Molecular therapy. Methods & clinical development , 2016 | Pubmed ID: 27933309
Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.
Molecular therapy : the journal of the American Society of Gene Therapy 10, 2017 | Pubmed ID: 28522034
Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration.
The Journal of neuroscience : the official journal of the Society for Neuroscience 07, 2017 | Pubmed ID: 28607168
Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Neurobiology of disease Oct, 2017 | Pubmed ID: 28711409
Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS.
Molecular therapy. Nucleic acids Sep, 2017 | Pubmed ID: 28918020
Can STN DBS protect both nigral somata and innervation of the striatum?
Annals of neurology 11, 2017 | Pubmed ID: 28985650
Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.
Scientific reports Nov, 2017 | Pubmed ID: 29180681
Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.
Journal of Parkinson's disease , 2018 | Pubmed ID: 29400668
Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.
Frontiers in molecular neuroscience , 2018 | Pubmed ID: 29497361
Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
Journal of neuroinflammation May, 2018 | Pubmed ID: 29716614
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.
Parkinsonism & related disorders 08, 2018 | Pubmed ID: 29759928
Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
Journal of neuroinflammation May, 2018 | Pubmed ID: 29843738
Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway.
Molecular & cellular proteomics : MCP 09, 2018 | Pubmed ID: 29915149
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease.
Frontiers in neuroscience , 2018 | Pubmed ID: 30233303
BDNF provides many routes toward STN DBS-mediated disease modification.
Movement disorders : official journal of the Movement Disorder Society 01, 2019 | Pubmed ID: 30440081
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Movement disorders : official journal of the Movement Disorder Society 05, 2019 | Pubmed ID: 31002755
Cell therapy for Parkinson's disease: Why it doesn't work every time.
Movement disorders : official journal of the Movement Disorder Society 08, 2019 | Pubmed ID: 31234239
Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Neurobiology of disease 10, 2019 | Pubmed ID: 31276792
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 04, 2020 | Pubmed ID: 32238479
Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
Experimental neurology 08, 2020 | Pubmed ID: 32387398
Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits.
Neurobiology of disease 07, 2020 | Pubmed ID: 32422283
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Neurobiology of disease Jan, 2021 | Pubmed ID: 33188920
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Oct, 2020 | Pubmed ID: 33215284
Striatal afferent BDNF is disrupted by synucleinopathy and partially restored by STN DBS.
The Journal of neuroscience : the official journal of the Society for Neuroscience Jan, 2021 | Pubmed ID: 33472823
Next-Generation Diamond Electrodes for Neurochemical Sensing: Challenges and Opportunities.
Micromachines Jan, 2021 | Pubmed ID: 33530395
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
JCI insight 03, 2021 | Pubmed ID: 33682798
Synucleinopathy-associated pathogenesis in Parkinson's disease and the potential for brain-derived neurotrophic factor.
NPJ Parkinson's disease Apr, 2021 | Pubmed ID: 33846345
Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.
Parkinsonism & related disorders 08, 2021 | Pubmed ID: 34218047
BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.
Neuromodulation : journal of the International Neuromodulation Society Jul, 2021 | Pubmed ID: 34288271
Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memory.
Translational psychiatry 03, 2022 | Pubmed ID: 35256586
Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
Movement disorders : official journal of the Movement Disorder Society May, 2022 | Pubmed ID: 35524682
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein.
NPJ Parkinson's disease May, 2022 | Pubmed ID: 35610264
Joseph R. Patterson1,
Nicole K. Polinski2,
Megan F. Duffy1,3,
Christopher J. Kemp1,
Kelvin C. Luk4,
Laura A. Volpicelli-Daley5,
Nicholas M. Kanaan1,
Caryl E. Sortwell1,3,6
1Department of Translational Science and Molecular Medicine, Michigan State University,
2, The Michael J. Fox Foundation for Parkinson's Research,
3Neuroscience Program, Michigan State University,
4Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine,
5Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham,
6, Mercy Health Hauenstein Neuroscience Medical Center
Joseph R. Patterson1,2,3,
Allyson Cole-Strauss1,2,3,
Nathan Kuhn1,2,
Carlene Mercier3,4,
Joseph Kochmanski1,2,
John A. Gerlach5,
Rhiannon M. LeVeque3,4,
Kerri A. Neugebauer3,4,6,
Kayla N. Conner3,4,
Jasper Gomez3,4,
Mark G. Hennes3,4,
Kaje’ne E. Thompson3,4,
Destinee L. Rytlewski3,4,
Chloe C. Bigwood3,4,
Amy Scharmen3,4,
Gabriel Simjanovski3,4,
Cassidy Riley3,4,
Jessica Donaldson3,4,
Dilann Yasin3,4,
Najwa Kouja3,5,
Zaria Contejean3,4,
Michaela Burnett3,4,
Shakhlo Aminova3,4,
Nat Ato Yawson3,4,7,
Simran B. Singh3,4,
Osama M. Alian3,4,
Carson D. Broeker3,4,8,
Erin K. Zaluzec3,4,7,
Morgan ONeill3,4,9,
Birgit Puschner10,
Aron Sousa2,
Laura Bix11,
Brian Jespersen2,
Claudia Holzman12,
Jade Mitchell13,
Ryan Julien13,
Yesim Askin14,
Danielle Barnes14,
Purna Durshanpalli14,
Doug Krum14,
Rett Weber14,
Morgan Patterson14,
Becky Anderson14,
Ryan Hunt14,
Benjamin O’Brien14,
Andrew Umstead1,2,
John S. Beck1,2,
Irving E. Vega1,2,
Caryl E. Sortwell1,2,
Jack W. Lipton1,2
1Department of Translational Neuroscience, Michigan State University,
2College of Human Medicine, Michigan State University,
3COVID-19 Early Detection Program, Michigan State University,
4Department of Microbiology and Molecular Genetics, Michigan State University,
5Biomedical Laboratory Diagnostics Program, Michigan State University,
6Department of Plant, Soil, and Microbial Sciences, Michigan State University,
7Department of Pharmacology and Toxicology, Michigan State University,
8Department of Biochemistry and Molecular Biology, Michigan State University,
9College of Osteopathic Medicine, Michigan State University,
10College of Veterinary Medicine, Michigan State University,
11School of Packaging, Michigan State University,
12Department of Epidemiology and Biostatistics, Michigan State University,
13Department of Biosystems Engineering, Michigan State University,
14Enterprise Services, Michigan State University
Natalie Landeck1,
Melissa Conti Mazza1,
Megan Duffy1,
Christopher Bishop2,
Caryl E. Sortwell3,
Mark R. Cookson1
1Cell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health,
2Behavioral Neuroscience Program, Department of Psychology, Binghamton University,
3Department of Translational Neuroscience, Mercy Health Hauenstein Neuroscience Medical Center, Michigan State University
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados